Epkinly market set for growth as targeted cancer therapies expand

The Business Research Company says the global Epkinly market is set to grow through 2026-2035, led by rising demand for targeted oncology treatments and broader use of bispecific antibodies. North America led the market in 2025, while Europe is projected to post the fastest growth.

Why it matters: - Epkinly is part of a wider shift toward precision cancer care, where treatments are designed to attack specific disease markers and may reduce some of the tradeoffs tied to traditional chemotherapy. - The market outlook points to stronger demand for therapies used in relapsed or refractory blood cancers, especially non-Hodgkin lymphoma. - The report signals where investment, adoption and clinical development are likely to concentrate next in hematologic oncology.

What happened: - The Business Research Company released its "Epkinly Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report says the global Epkinly market is entering a growth phase driven by rising use of immuno-oncology therapies and expanding applications for bispecific antibodies. - The analysis says North America led the global Epkinly market in 2025. - The report projects Europe will be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

The details: - Epkinly is the brand name for epcoritamab. - Epkinly is a monoclonal antibody used to treat certain cancers, including relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma and other non-Hodgkin lymphoma subtypes. - The drug targets CD3 on T cells and CD20 on B cells. - That dual targeting helps the immune system recognize and attack cancer cells. - Historical market growth has been tied to the rising prevalence of non-Hodgkin lymphoma, limitations of traditional chemotherapy, advances in monoclonal antibody research, more approvals for targeted oncology drugs and unmet needs in relapsed cancer treatment. - The forecast period is expected to benefit from broader clinical use of immuno-oncology therapies, improved patient outcome data, rising oncology spending and more specialized cancer centers. - Key trends cited in the report include bispecific antibody immunotherapies, T-cell engaging oncology drugs, targeted treatment for relapsed and refractory lymphomas, subcutaneous administration and personalized treatment strategies for hematologic cancers. - The report says rising preference for targeted therapies is a major growth driver because these treatments aim at specific disease molecules and can reduce side effects versus conventional therapy. - The report also highlights market intelligence features in its 2026 reports, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The report frames Epkinly as one example of how oncology pipelines are moving toward targeted, immune-based therapies rather than broad chemotherapy approaches. - The strongest growth signals are tied less to one drug alone and more to the expanding category of bispecific and T-cell engaging treatments. - Regional leadership in North America and faster projected growth in Europe suggest the market is following both current infrastructure and future reimbursement or adoption potential.

What's next: - The market forecast runs through 2035 and will likely be shaped by new indications, broader clinical adoption and additional outcome data. - The report suggests the next phase of competition will center on delivery methods, precision targeting and use across harder-to-treat lymphoma subtypes. - The Business Research Company says its team is available for additional questions and report inquiries.